Introduction {#S0001}
============

Colorectal cancer (CRC) is the third most frequently diagnosed malignancy both in men and in women and represents one of the leading causes of cancer-related mortality worldwide.[@CIT0001] In recent years, an extended molecular characterization of CRC has led to a deeper understanding of the mechanisms of development and heterogeneity of this disease. Novel targeted agents including vascular endothelial growth factors (VEGF)-, epidermal growth factor receptor (EGFR)- and more recently immune checkpoints-inhibitors have become available for the treatment of mCRC, adding to standard chemotherapy with 5-fluorouracil, oxaliplatin and irinotecan.[@CIT0002] The improvement in medical treatments, together with enhanced locoregional and surgical approaches, has translated into a longer median overall survival (OS) of patients with mCRC which has surpassed 30 months in modern day practice.[@CIT0003]

The EGFR signaling pathway plays a critical role in CRC development and EGFR inhibitors are well established therapeutic agents in mCRC treatment. Panitumumab is a fully human monoclonal antibody (mAb) which targets with high affinity the extracellular domain of EGFR, competitively inhibiting the binding of other ligands and thus preventing the activation of the EGFR downstream signaling cascade ([Figure 1](#F0001){ref-type="fig"}).[@CIT0004] In malignant cells the activation of EGFR promotes cell proliferation through the KRAS/RAF/MAPK and the PI3K/AKT/mTOR axes.[@CIT0005] EGFR blockade by panitumumab results in inhibition of cell growth, induction of apoptosis, decreased of proinflammatory cytokines and VEGF production, and EGFR downregulation through receptor internalization.[@CIT0006],[@CIT0007] Over time, the clinical efficacy of panitumumab in mCRC has been proven by several randomized trials across different treatment lines, however since early studies it was clear that not all patients benefit from this treatment. Hence, the identification of predictive biomarkers has been paramount in panitumumab studies, paving the way to the discovery of *rat sarcoma* (*RAS*) mutations as negative predictive biomarkers for anti-EGFRs activity.[@CIT0008]Figure 1Panitumumab, a fully humanized monoclonal IgG2 antibody, inhibits the EGFR pathway.**Abbreviations:** AKT, AKT8 virus oncogene cellular homolog; EGFR, epidermal growth factor receptor; ERK, extracellular signal--regulated kinase; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidyilinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAF, v-Raf murine sarcoma viral oncogene homolog; RAS, rat sarcoma viral oncogene homolog.

In this review, we will provide an overview of panitumumab activity across different treatment scenarios and treatment lines in mCRC. We will also address the impact of panitumumab treatment on patients' quality of life (QoL) and discuss novel perspectives on patient selection and primary and secondary resistance mechanisms to anti-EGFR agents.

Regulatory approval and molecular patient selection {#S0002}
===================================================

Panitumumab is currently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of *RAS* wild-type (WT) mCRC in combination with FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin and irinotecan) in the first-line setting; in combination with FOLFIRI in the second-line setting; and as monotherapy following disease progression after prior chemotherapy treatment (fluoropyrimidine-, oxaliplatin- and irinotecan-containing regimens).[@CIT0004]

Regulatory Agencies have also provided recommendations on validated laboratory techniques and accreditation criteria for *RAS* mutation testing, which should be performed only in highly qualified and certified laboratories. In 2017, the American Society of Clinical Oncology (ASCO) in collaboration with the Association for Molecular Pathology, the College of American Pathologists, and the American Society for Clinical Pathology, published a set of dedicated guidelines on the evaluation of molecular biomarkers in CRC.[@CIT0009] According to the current standard of practice every patient being considered for anti-EGFR treatment must receive *RAS* mutational testing and the analysis should include *KRAS* and *NRAS* codons 12, 13 of exon 2; 59, 61 of exon 3; and 117 and 146 of exon 4.[@CIT0008]

More recently, several other tumor molecular features and mutations in genes involved in EGFR-related pathways have been shown to play a role in anti-EGFRs resistance mechanisms. The *V-Raf murine sarcoma viral oncogene homolog B1* (*BRAF*) V600E mutation is one of these, and growing evidence supports the use of *BRAF* as a negative predictive biomarker in clinical practice. An overview of novel biomarkers of primary and acquired resistance mechanisms is provided in the next sections.

Clinical efficacy {#S0003}
=================

Panitumumab monotherapy {#S0003-S2001}
-----------------------

The open label phase III 408 trial was the first study to demonstrate a progression-free survival (PFS) benefit, although small, with single agent panitumumab compared to best supportive care (BSC) in unselected pre-treated mCRC (8 versus 7.3 weeks, hazard ratio (HR) 0.54; 95% confidence interval (CI), 0.44--0.66; *P\<0*.0001).[@CIT0010] Later on, a retrospective biomarker analysis from this study shed light on the predictive role of *KRAS* exon 2 mutation on panitumumab efficacy, demonstrating a clear improvement in PFS for patients with WT tumors (12.3 versus 7.3 weeks, HR 0.45; 95% CI, 0.34--0.59; *P*\<0.0001), while no benefit was observed in patients with mutated tumors (PFS 7.4 versus 7.3 weeks for panitumumab versus BSC, HR 0.99; 95% CI, 0.73--1.36).[@CIT0011] These findings opened a new era for biomarker discovery and molecular patient selection, leading the restriction of the use of anti-EGFR agents to *KRAS* exon 2 (codon 12 and 13) WT tumors in 2008.

The activity of panitumumab monotherapy has been compared to that of cetuximab, the first approved anti-EGFR agent, in an open-label randomized phase III trial in patients with chemotherapy-refractory *KRAS* exon 2 WT mCRC.[@CIT0012] Panitumumab was non-inferior to cetuximab in terms of OS, PFS, and objective response rate (ORR), with reported OS of 10.4 months and 10 months, respectively (HR 0.97, 95% CI 0.84--1.11, *P*=0.0007).

Combination therapy {#S0003-S2002}
-------------------

Shortly after the 408 study, several trials evaluated the efficacy of panitumumab in association with chemotherapy doublets, showing significant benefit from the addition of panitumumab compared to chemotherapy alone in *KRAS* exon 2 WT patients, both in first- and in second-line settings (efficacy data of main trials are summarized in [Table 1](#T0001){ref-type="table"}).Table 1Efficacy results from main panitumumab trialsTrial (phase)\
RefTreatment Arms (n.)Treatment\
LinePrimary EndpointORR (%)PFSOS*KRAS* ex 2 WT*RAS* WT*KRAS* ex 2 WT*RAS* WT*KRAS* ex 2 WT*RAS* WT408 (III)\
NCT00113763\
[@CIT0010]^,^[@CIT0011]^,^[@CIT0020]Panitumumab (n.231)\
BSC (n.232)3rd/+PFS17%\
0%17%\
0%2.87 m (n.124)\
1.7 m (n.119)\
\[HR 0.45; *P*\<0.0001\]HR 0.39; 95% CI, 0.27--0.56; *P*\<0.0018.1 m (n.124)\
7.6 m (n.119)\
\[HR 0.99; 95% CI, 0.75--1.29\]Not reported0007 (III)\
NCT01412957\
[@CIT0080]Panitumumab (n.189)\
BSC (n.188)3rd/+OS27%\
1.6%\
\[*P*\<0.0001\]31%\
2.3%\
\[*P*\<0.0001\]3.6 m (n.189)\
1.7 m (n.188)\
\[HR 0.51; *P*\<0.0001\]5.2 m (n.142)\
1.7 m (n.128)\
\[HR 0.46; *P*\<0.0001\]10 m (n.189)\
7.4 m (n.188)\
\[HR 0.73; *P*=0.0096\]10 m (n.142)\
6.9 m (n.128)\
\[HR 0.70; *P*=0.0135\]ASPECCT (III)\
NCT01001377\
[@CIT0012]Panitumumab (n.499)\
Cetuximab (n.500)3rd/+OS22%\
20%NE4.1 m (n.499)\
4.4 m (n.500)\
\[HR 1.00; 95% CI, 0.88--1.14\]NE10.4 m (n.499)\
10 m (n.500)\
\[HR 0.97; Z-score −3.19; *P*=0.0007\]NEPRIME (III)\
NCT00364013\
[@CIT0015]^,^[@CIT0016]FOLFOX + Panitumumab (n.593)\
FOLFOX (n.590)1stPFS57%\
48%\
\[*P*=0.02\]Not reported10.0 m (n.325)\
8.6 m (n.331)\
\[HR 0.80; *P*=0.01\]10.1 m (n.259)\
7.9 m (n.253)\
\[HR 0.72; *P*=0.004\]23.8 m (n.325)\
19.4 m (n.331)\
\[HR 0.83; *P*=0.03\]25.8 m (n.259)\
20.2 m (n.253)\
\[HR 0.77; *P*=0.009\]314 (II)\
NCT00508404\
[@CIT0019]^,^[@CIT0047]FOLFIRI + Panitumumab (n.154)1stORR56%59%8.9 m (n.86)11.2 m (n.68)Not ReportedNot reportedPEAK (II)\
NCT00819780\
[@CIT0025]^,^[@CIT0026]FOLFOX + Panitumumab (n.142)\
FOLFOX + Bevacizumab (n.143)1stPFS57.8%\
53.5%65%\
60%10.9 m (n.142)\
10.1 m (n.143)\
\[HR 0.87; *P*=0.35\]12.8 m (n.88)\
10.1 m (n.82)\
\[HR 0.68; *P*=0.029\]34.2 m (n.142)\
24.3 m (n.143)\
\[HR 0.62; *P*=0.009\]36.9 m (n.88)\
28.9 m (n.82)\
\[HR 0.76; *P*=0.15\]PLANET-TTD (II)\
NCT00885885\
[@CIT0028]FOLFOX + Panitumumab (n.38)\
FOLFIRI + Panitumumab (n.39)1stORR74%\
67%78%\
73%13 m (n.38)\
14 m (n.39)\
\[HR 0.90; *P*=0.728\]13 m (n.27)\
15 m (n.26)\
\[HR 0.70; *P*=0.307\]37 m (n.38)\
41 m (n.39)\
\[HR 1.0; *P*=0.966\]39 m (n.27)\
49 m (n.26)\
\[HR 0.9; *P*=0.824\]VOLFI (II)\
NCT01328171\
[@CIT0035]mFOLFOXIRI + Panitumumab (n.63)\
mFOLFOXIRI (n.33)1stORR-87.3%\
60.6%; \[*P*=0.0041\]-9.7 m (n.63)\
10.1 m (n.33)\
\[HR 0.92; *P*=0.72\]Not ReportedNot Reported181 (III)\
NCT00339183\
[@CIT0013],[@CIT0014],[@CIT0081]FOLFIRI + Panitumumab (n.591)\
FOLFIRI (n.595)2ndPFS, OS35%\
10%\
\[*P*\<0.0001\]41%\
10%5.9 m (n.303)\
3.9 m (n.294)\
\[HR 0.73; *P*=0.004\]6.4 m (n.208)\
4.6 m (n.213)\
\[HR 0.70; *P*=0.007\]14.5 m (n.303)\
12.5 m (n.294)\
\[HR 0.85; *P*=0.12\]16.2 m (n.303)\
13.9 m (n.294)\
\[HR 0.81; *P*=0.08\]SPIRITT (II)\
NCT00418938\
[@CIT0082]FOLFIRI + Panitumumab (n.91)\
FOLFIRI + Bevacizumab (n.91)2ndPFS32%\
19%NE7.7 m (n.91)\
9.2 m (n.91)\
\[HR 1.01; *P*=0.97\]NE18 m (n.91)\
21.4 m (n.91)\
\[HR 1.06; *P*=0.75\]NE[^1]

The phase III randomized 181 trial compared second-line treatment with panitumumab-FOLFIRI to FOLFIRI alone.[@CIT0013] The study was later amended to prospectively evaluate *KRAS* exon 2 status as a predictor of panitumumab efficacy. In the *KRAS* WT population, a significant improvement in PFS was observed when panitumumab was added to chemotherapy (median PFS 5.9 versus 3.9 months, HR 0.73; 95% CI, 0.59--0.90; *P*=0.004); response rate was also improved to 35% versus 10% by the addition of panitumumab. A non-significant trend toward increased OS was observed for the panitumumab arm: median OS 14.5 versus 12.5 months, HR 0.85, 95% CI, 0.70--1.04; *P*=0.12. Conversely, no benefit was observed in patients whose tumors harbored a *KRAS* mutation.[@CIT0014]

In the first-line setting, the phase III randomized PRIME study demonstrated the benefit of combining panitumumab with FOLFOX-4 compared to FOLFOX-4 alone in *KRAS* exon 2 WT mCRC.[@CIT0015],[@CIT0016] Further efficacy analysis of this study, based on a more extensive patient molecular selection after the emerging evidence on the role of rare *RAS* activating mutations (*KRAS* exon 3 and 4, *NRAS* exon 2, 3 and 4) and *BRAF* mutations in anti-EGFRs resistance,[@CIT0017] proved for the first time a striking advantage from panitumumab treatment in the extended *RAS* WT population and lack of efficacy in *RAS*-mutated tumors. Notably, in 446 *RAS/BRAF* WT patients, panitumumab was shown to confer a greater magnitude of OS benefit compared to *KRAS* exon 2 WT, with an impressive 7.4 months improvement over chemotherapy alone (28.3 versus 20.9 months, HR 0.74; 95% CI, 0.57--0.96; *P*=0.02).[@CIT0018] The presence of a *BRAF* mutation was also confirmed as an independent negative prognostic factor both for PFS and OS, irrespective of treatment.

Similar results were obtained from updated molecular analyses of randomized first-,[@CIT0019] second-[@CIT0014] and third-line[@CIT0020] trials. A meta-analysis also confirmed the presence of extended *RAS* mutations as negative predictive biomarkers for anti-EGFRs activity in mCRC, with no difference between *KRAS* exon 2 mutations and other *KRAS* or *NRAS* mutations.[@CIT0021] These data led to the FDA restriction for the use of panitumumab to extended *KRAS* and *NRAS* WT mCRC. More recently, evidence on the role of *BRAF*V600E mutation as a biomarker of resistance to anti-EGFR agents has been confirmed by large meta-analyses showing a lack of treatment benefit from anti-EGFR mAbs, both in terms of PFS and OS, for *BRAF*-mutated mCRC.[@CIT0022]--[@CIT0024]

Both anti-EGFRs and anti-VEGF agents are approved for the first-line treatment of *RAS* WT mCRC in association with chemotherapy and have recently been compared in different head-to-head randomized trials. The phase II PEAK study investigated the addition of panitumumab versus bevacizumab to FOLFOX chemotherapy in the first-line setting.[@CIT0025] Although not designed to prove the superiority of one treatment over the other, this study showed a significant improvement in PFS (13.1 versus 10.1 months, HR 0.61; 95% CI, 0.42--0.88; *P*=0.0075), and a trend towards OS (41.3 versus 28.9 months, HR 0.70; 95% CI, 0.48--1.04; *P*=0.08) from panitumumab versus bevacizumab in the extended *RAS*/*BRAF* WT population, suggesting a survival benefit from first-line use of panitumumab in association to chemotherapy in these patients.[@CIT0026] A recent exploratory pooled analysis evaluating the effect of sequence of biological therapies on OS in patients with *RAS* or *RAS*/*BRAF* WT mCRC treated with panitumumab across the PRIME, PEAK and 181 trials, confirmed a trend towards improved OS for first-line panitumumab plus chemotherapy followed by second-line VEGF inhibitors, compared with first-line bevacizumab followed by second-line anti-EGFRs.[@CIT0027] Large prospective randomized trials are warranted to further evaluate the optimal first-/second-line targeted treatment sequence in *RAS* WT mCRC. Of interest, the ongoing CR-SEQUENCE trial from the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), evaluating the efficacy of FOLFOX plus panitumumab followed by FOLFIRI plus bevacizumab (Sequence 1) versus FOLFOX plus bevacizumab followed by FOLFIRI plus panitumumab (Sequence 2) in untreated patients with unresectable *RAS* WT left-sided mCRC (NCT03635021).

Of note, panitumumab treatment was consistently associated with higher early tumor shrinkage (ETS) rates and greater depth of response (DpR) in a large retrospective analysis of patients with *RAS* WT mCRC from the randomized first-line PRIME, PEAK and PLANET[@CIT0028] trials. Irrespective of treatment, ETS and DpR were associated with improved PFS, OS and resection rates in this analysis, suggesting that achieving these endpoints during first-line treatment is linked with favorable outcomes.[@CIT0029]

In the third-line setting, regorafenib and trifluridine/tipiracil are recommended after progression to standard cytotoxic and targeted treatments. However, in *RAS* WT patients not previously treated with anti-EGFR antibodies, cetuximab in combination with irinotecan or panitumumab monotherapy may be considered as a third-line. Of interest, in the context of the *continuum* of care of mCRC patients, several studies and case reports have reported data about different treatment strategies in second- or third-line, including the reintroduction or re-challenge with cetuximab or panitumumab in patients who have been previously treated with anti-EGFR drugs as a first-line.[@CIT0030],[@CIT0031] Despite promising results, further perspective trials are warranted to establish the role of this strategy in the third-line setting in *RAS* WT mCRC patients (see paragraph 6).[@CIT0032]

Combination with intensified chemotherapy {#S0003-S2003}
-----------------------------------------

Panitumumab has also been tested in combination with the triple chemotherapy regimen FOLFOXIRI in several small studies.

In 2013, a single arm phase II trial enrolled 37 patients with quadruple WT (*KRAS, NRAS, HRAS, BRAF*) initially unresectable mCRC to receive treatment with panitumumab in association to a modified FOLFOXIRI regimen.[@CIT0033] Median PFS was 11.3 months. The ORR, primary endpoint of the study, was 89% with one complete response, allowing 16 metastases resection, 13 of which (35%) R0. Another single arm phase II trial assessing the efficacy of FOLFOXIRI plus panitumumab in *RAS* WT tumors was published in 2016.[@CIT0034] ORR was 59% (no complete responses) and 10 patients (66%) underwent surgery and secondary R0 resection. Median PFS was 13.3 months.

More recently, promising results were presented from the randomized phase II VOLFI trial, which enrolled 96 patients with unresectable *RAS* WT mCRC to receive either mFOLFOXIRI plus panitumumab or FOLFOXIRI alone.[@CIT0035] First-line treatment with mFOLFOXIRI plus panitumumab resulted in significantly higher ORR compared to chemotherapy alone (87.3% versus 60.6%; OR: 4.47; 95% CI, 1.61--12.38; *P*=0.0041), and higher disease control rate (DCR) (97% versus 79%, *P*=0.0071). Secondary resection rates were 33.3% in the anti-EGFR arm (61.9% R0) versus 12.1% in the chemotherapy-only arm in the overall population, and 75% versus 36.4% in the potentially resectable cohort. Median PFS was not significantly different between treatment arms in the overall population.

To clarify whether the intensification of chemotherapy treatment in combination with panitumumab may be beneficial, two trials are currently ongoing. The phase III TRIPLETE trial is testing the efficacy of FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab in previously untreated *RAS/BRAF* WT mCRC (NCT03231722). The phase II PANIRINOX trial is assessing treatment with FOLFIRINOX plus panitumumab versus mFOLFOX6 plus panitumumab (NCT02980510). Results of these trials are warranted to further evaluate the efficacy and safety of this intensified treatment strategy.

Maintenance treatment {#S0003-S2004}
---------------------

Maintenance treatment with the anti-VEGF bevacizumab in combination with a fluoropyrimidine after a period of induction therapy in patients with a good response to the initial treatment has become a standard of care for mCRC and is included in main international guidelines. On the other hand, there is less evidence on maintenance strategies involving anti-EGFR mAbs.

The role of continuing panitumumab as a maintenance therapy after first-line treatment was firstly evaluated in a retrospective analysis of patients from the PRIME and PEAK trials receiving maintenance therapy with panitumumab plus 5-fluorouracil/leucovorin (5-FU/LV).[@CIT0036] Overall, the median duration of panitumumab maintenance was 21 weeks (interquartile range: 11--41). The analysis showed an OS and PFS benefit in continuing the administration of panitumumab in addition to 5-FU/LV versus chemotherapy ± bevacizumab, with PRIME patients having a median OS of 40.2 versus 24.1 months and PEAK patients a median OS of 39.1 versus 28.9 months, respectively.

More recently, the phase II VALENTINO study investigated the efficacy of a maintenance treatment with 5FU/LV plus panitumumab versus single-agent panitumumab following first-line FOLFOX plus panitumumab in patients with *RAS* WT mCRC. This study showed that maintenance with panitumumab alone following induction with FOLFOX plus panitumumab achieves inferior PFS than the 5FU/LV plus panitumumab combination: 10-months PFS 52.8% versus 62.8%, median PFS 10.2 versus 13 months, respectively (*P=0*.011).[@CIT0037]

Data from the Japanese phase II SAPPHIRE trial, where patients not progressing after 6 cycles of FOLFOX plus panitumumab were randomized to receive 5-FU/LV and panitumumab as maintenance therapy or to continue induction treatment, showed similar 9-months PFS in the two arms, thus supporting the use of panitumumab plus 5-FU/LV as a maintenance treatment in order to delay disease progression while preventing the occurrence of oxaliplatin-induced neuropathy.[@CIT0038]

Tumor sidedness in panitumumab trials {#S0003-S2005}
-------------------------------------

Over the past few years, several studies highlighted the prognostic value of primary tumor location (left colon versus right colon) and data have focused on location as a potential predictive biomarker for anti-EGFRs activity, especially in the first-line setting. In particular, left-sided primary tumors have been shown to have better prognosis and improved treatment outcomes from the use of EGFR inhibitors in addition to combination chemotherapy.

Data from 927 patients with extended *RAS* WT mCRC enrolled in three randomized trials on panitumumab (PRIME, PEAK and 181) showed that the overall prognosis was worse for right-sided tumors than for left-sided ones, regardless of treatment. The addition of panitumumab to chemotherapy led to striking PFS and OS outcomes in left-sided tumors; conversely, patients with *RAS* WT right-sided primary tumors derived no benefit from the addition of anti-EGFRs to chemotherapy. A higher proportion of patients with right-sided tumors harbored *BRAF* mutations, thus contributing to the worse prognosis of this group, nevertheless, similar efficacy data were also obtained in the *RAS/BRAF* WT population.[@CIT0039] Similar results were found consistently across several different trials of panitumumab in second- and later-lines of treatment,[@CIT0040] and trials investigating cetuximab-based treatments.[@CIT0041] A more recent retrospective analysis of patients with *RAS* WT mCRC from the PRIME and PEAK trials further evaluated the effects of primary tumor location on ETS, DpR, and long-term survival. First-line panitumumab was associated with improved ETS (PRIME: 62% versus 36%; PEAK: 58% versus 41%) and DpR (PRIME: 59% versus 49%; PEAK: 70% versus 48%) in patients with left-sided mCRC, and panitumumab treatment consistently predicted long-term survival. Notably, in the pooled analyses of the studies, more patients with right-sided disease achieved ETS if treated with panitumumab than comparator (39% versus 29%), thus ETS may identify a subgroup of patients with right-sided disease who might respond to panitumumab.[@CIT0042]

Large meta-analyses of first-line trials comparing chemotherapy plus bevacizumab to chemotherapy plus anti-EGFRs have shown a significant benefit in ORR, PFS and OS in patients with left-sided primary tumors treated with anti-EGFR mAbs compared to bevacizumab, whereas right-sided tumors have been shown to be a negative prognostic indicator for OS for all treatments and to benefit more from bevacizumab treatment.[@CIT0043],[@CIT0044]

Several hypotheses have been proposed to explain these findings, involving the role of different embryogenic origin, the association of right-sided tumors with specific molecular phenotypes (particularly, CMS1-immune and CMS3-metabolic), different methylation signatures and the distinct microbiota in right versus left colon, supporting the role of tumor sidedness as a surrogate for tumor biology.[@CIT0045]

A limitation of these data is the unplanned retrospective nature of the abovementioned analyses, however, in light of their consistency across a number of different randomized trials, NCCN guidelines have recently incorporated into their recommendation to exclude anti-EGFR antibodies in the first-line treatment of right-sided *RAS* WT mCRC.[@CIT0002]

It has to be noted, however, that when selecting the optimal treatment strategy for a *RAS* WT mCRC patient a comprehensive evaluation of the clinical scenario, treatment goals, expected toxicities and patients' characteristics and preferences must be taken into account, leading to a personalized approach that may favor, for instance, an anti-VEGF therapy as first-line for a left-sided *RAS* WT mCRC, saving anti-EGFR agents for a later treatment line.

Quality of life, safety and tolerability {#S0004}
========================================

Anti-EGFR therapy frequently results in skin-related toxicities (eg acneiform rash, xerosis, paronychia). These side effects can negatively affect treatment compliance and patients' quality of life (QoL)[@CIT0046] and it is important to evaluate how the impact of such adverse events weigh against the benefits of panitumumab in mCRC patients. Therefore, maintenance of QoL is an important objective in clinical trials and patient-reported outcomes (PROs) are a useful way of measuring the impact of treatment on QoL.

Study 314 was a single-arm, multicenter, phase II study evaluating the efficacy and safety of panitumumab plus FOLFIRI as first-line treatment for patients with mCRC.[@CIT0047] In this trial, QoL was measured using the EuroQoL 5-domain (EQ-5D) and the EORTC QoL Questionnaires (QLQ-C30) as an exploratory endpoint. Notably, panitumumab plus FOLFIRI had minimal impact on patients' QoL, as EQ-5D and QLQ-C30 scores remained stable throughout the study despite the high incidence of skin-related toxicity.[@CIT0048]

In the PRIME trial,[@CIT0015] QoL was assessed as a prespecified tertiary endpoint, using the EQ-5D health state index (HSI) and overall health rating (OHR) measures. There were no statistically significant differences between the panitumumab plus FOLFOX4 and FOLFOX4 arms in HSI or OHR scores from baseline to progression or to discontinuation.[@CIT0049] Of interest, in this study the authors assessed whether skin toxicities and early tumor shrinkage (ETS) may have had impact on QoL. However, no significant differences in QoL outcomes were observed between patients with grade (G) 0--2 skin toxicity and those with G3+ skin toxicity, as well as no difference in QoL for those with ETS versus those without ETS. Nonetheless, patients with tumor-related symptoms at baseline who experienced ETS showed a statistically meaningful improvement in QoL compared with those who did not have ETS.

The evaluation of changes in health-related QoL (HRQoL) using the EQ-5D was a tertiary objective also in the second-line phase III 181 trial.[@CIT0013] A total of 530 patients (263 treated with panitumumab plus FOLFIRI and 267 with FOLFIRI) were included in the HRQoL analysis, representing 88.8% of the overall *KRAS* WT population. There were no statistically significant or clinically meaningful overall differences in the change in HRQoL when comparing treatment arms. In addition, regardless of the severity of skin toxicity, patients treated with panitumumab maintained a similar HRQoL.[@CIT0050]

Panitumumab has also been reported to provide better control of symptoms and maintenance of HRQoL compared with BSC alone in patients with chemorefractory *KRAS* WT mCRC.[@CIT0051]

Taken together, these data suggest that the addition of panitumumab to chemotherapy regimens as a first-, second- or later-line treatment of patients with *RAS* WT mCRC provides improvements in survival outcomes without compromising HRQoL.

Safety and tolerability data are available from clinical trials evaluating panitumumab as a monotherapy or in combination with chemotherapy in mCRC. Based on a pooled analysis of patients enrolled in panitumumab trials (n=2,224), the most commonly reported adverse reactions (AE) are skin reactions occurring in approximately 94% of patients, including rash (47%), dermatitis acneiform (39%), pruritus (36%), erythema (33%), dry skin (21%), and paronychia (20%). Other very commonly reported AE occurring in ≥20% of patients are diarrhea (46%), nausea (39%), vomiting (26%), constipation (23%), abdominal pain (23%), fatigue (35%), pyrexia (21%), and decreased appetite (30%).[@CIT0052]

In phase II trials, the most frequent panitumumab-related AE involved skin (92--96%), nails (28--30%), eyes (8--17%), hair (8%).[@CIT0053] EGFR is expressed in normal skin cells; therefore, dermatologic AE are directly linked to EGFR blockade. Acneiform rash usually appears after the first treatment administration, while paronychia and desquamation usually appear by the fourth week of treatment.[@CIT0054] In a pooled analysis of 920 patients treated with panitumumab monotherapy included in ten phase I-III clinical trials most patients experienced G1--2 skin toxicities that rarely resulted in treatment discontinuation. Importantly, the development of skin toxicities ≥G2 has been associated with improved PFS and OS;[@CIT0055] therefore, it is considered a strong predictive biomarker of clinical benefit in patients treated with EGFR inhibitors.

Since these toxicities can result in treatment discontinuation and can potentially affect the patient's QoL, increase patient risk for additional infections, and lead to suboptimal anti-EGFR schedules -all of which may affect clinical outcomes- their management should be an important focus when administering these agents.[@CIT0056] Hence, novel strategies to reduce the incidence and the severity of skin toxicity have been developed based on the STEPP[@CIT0054] (Skin Toxicity Evaluation Protocol with Panitumumab) and J-STEPP[@CIT0057] randomized studies. The randomized phase II STEPP study evaluated the impact of a pre-emptive strategy (primary prophylaxis) including skin moisturizers, sunscreen, topical steroids, and doxycycline for the duration of anti-EGFR therapy, versus a reactive treatment after toxicity occurrence.[@CIT0054] The pre-emptive strategy significantly reduced the incidence of ≥G2 skin toxicity at 6 weeks compared to standard care (29% versus 62%, respectively). Similarly, the Japanese open-label, multicenter, randomized J-STEPP study showed that the cumulative incidence of ≥G2 skin toxicities in 6 weeks was 21.3% in the pre-emptive group compared with 62.5% in the reactive group (RR=0.34; 95% CI, 0.19--0.62; *P*\<0.001).[@CIT0057]

Panitumumab administration should be withheld at the first occurrence of G3 skin toxicities. Re-introduction of panitumumab at the original dose is recommended once toxicity has subside, while dose reduction is recommended upon subsequent occurrence of G3 toxicities (80% of the original dose at the second occurrence and 60% at the third occurrence).[@CIT0004] Discontinuation of treatment is implemented at the forth occurrence or if G3 skin toxicities do not recover after 1--2 withheld doses.

When panitumumab is administered as monotherapy severe diarrhea is uncommon, however its incidence increases when panitumumab is associated with chemotherapy. In fact, G3--4 diarrhea occurred in up to 28% of patients in trials combining an EGFR inhibitor with chemotherapy.[@CIT0058]

Another common AE that may occur during panitumumab treatment is hypomagnesemia, due to the effects of EGFR inhibition in the ascending loop of Henle and in the distal convoluted renal tubule. Incidence of hypomagnesemia can be up to 28--36% and was found to be associated with treatment duration.[@CIT0059] In most cases panitumumab-induced hypomagnesemia is asymptomatic, however for patients who experience a symptomatic ≥G2 hypomagnesemia, oral or intravenous replacement should be considered. Of interest, early onset of hypomagnesemia during anti-EGFR treatment has been associated with treatment efficacy.[@CIT0060]

Panitumumab is a fully human mAb, hence incidence of infusion-related reactions is very low (1--3%). The use of routine premedication before the administration of panitumumab is recommended if a previous infusion reaction has occurred.[@CIT0004]

Panitumumab in the elderly population {#S0005}
=====================================

Despite the high prevalence of CRC in the elderly population, these patients have been underrepresented in clinical trials and their optimal treatment is yet to be determined, with only few data available on anti-EGFR treatment in combination with chemotherapy. In the daily practice, treatment of older cancer patients is challenging and a careful assessment of patients' performance status, comorbidities, age-related organ function, life expectancy, potential treatment-related toxicity and QoL issues should be implemented in the decision making to select those patients who could benefit from treatment.

The use of panitumumab as monotherapy in the first-line setting in elderly and frail patients was investigated by Sastre and colleagues, who treated 33 *KRAS* WT patients over 70 years of age with an ECOG functional status up to 3 in a single arm phase II trial. Treatment with panitumumab was demonstrated to be an active and safe option in this group of patients. ORR was 9.1% with a 6-months PFS rate of 53.3% and median OS of 12.3 months in the extended *RAS* WT patients.[@CIT0061] Encouraging data were also reported in another study investigating panitumumab monotherapy in molecularly selected *RAS* and *BRAF* WT frail elderly patients deemed unfit for chemotherapy.[@CIT0062]

However, data on the adoption of chemotherapy plus anti-EGFRs in elderly mCRC patients are scarce. In the subgroup analysis of *RAS* WT patients from the PRIME study the combination of FOLFOX-4 and panitumumab showed a benefit over FOLFOX-4 in the subset of patients aged more than 65 years (n=188), in terms of OS (26.6 versus 17.4 months; HR 0.78; 95% CI, 0.58--1.09), PFS (9.7 versus 9.2 months; HR 0.88; 95% CI, 0.65--1.19) and ORR (49% versus 42%), without raising any safety concern.[@CIT0063] Positive results in terms of tolerability and efficacy were also recently reported in a retrospective study of 100 patients aged over 70 years (95.4% ECOG performance status 0--1) treated with doublet chemotherapy plus panitumumab, with a median PFS of 9.4 months (95% CI, 7.8--11.0) and a median OS of 23.0 months (95% CI, 20.6--25.3).[@CIT0064]

To clarify the safety and efficacy of panitumumab in association with chemotherapy in the elderly population a dedicated trial, the phase II PANDA study (NCT02904031), is currently ongoing, enrolling patients over 70 years of age with an ECOG performance status 1 or 2 if aged 70 to 75 years and an ECOG performance status 0 or 1 if aged \>75 years. In this study elderly patients with a diagnosis of *RAS* and *BRAF* WT mCRC are randomized to a first-line treatment with panitumumab in combination with FOLFOX or 5FU/LV. Of note, **s**econdary endpoints of the study include the evaluation of the prognostic role of geriatric assessment tools and toxicity risk scores to aid patient selection in the elderly population. Safety and efficacy results of this trial are warranted to inform targeted treatment choices in elderly patients.

Novel mechanisms of resistance and future perspectives {#S0006}
======================================================

Several additional mechanisms of primary resistance to anti-EGFRs have been identified in *RAS* WT mCRC so far, based on preclinical data and retrospective evaluations. However, the routine use of these biomarkers in clinical practice is not recommended at present, and further prospective validation is warranted. These include *HER2* amplification, *PIK3CA* mutations (exon 9 and 20), *MET* amplification, *FGFR1* and *PDGFRA* mutations and loss of *PTEN* function.[@CIT0065] *HER2* amplification, in particular, has recently gained attention as a promising druggable target in mCRC. Based on a strong pre-clinical rationale,[@CIT0066] the proof-of-concept phase II HERACLES trial has shown promising activity of a combined HER2 blockade with trastuzumab and lapatinib in treatment-refractory *HER2*-positive mCRC.[@CIT0067] Notably, all patients enrolled in the trial received previous EGFR inhibitors and none of those evaluable for response achieved an objective response to either panitumumab or cetuximab, supporting the role of *HER2* amplification as a resistance mechanism to anti-EGFRs. Several trials are currently investigating HER2 blockade strategies in *HER2*-amplified mCRC, opening new perspectives for this subset of patients. Other novel treatment strategies combining EGFR inhibitors with different targeted agents (ie panitumumab plus the mTOR inhibitor everolimus;[@CIT0068] or panitumumab plus BRAF and MEK inhibition in *BRAF*V600E-mutant tumors[@CIT0069]), aiming to overcome primary resistance to anti-EGFR agents, are also under investigation.

More recently, a panel of multiple combined genomic alterations comprising activating mutations of the MAPKs or PI3K/AKT axis, *NTRK/ROS1/ALK/RET* rearrangements, *HER2* amplification or mutations, and *MET* amplification (the PRESSING panel), has been shown to be able to predict primary resistance to anti-EGFRs in *RAS*/*BRAF* WT mCRCs.[@CIT0070] Additionally, a right-sided primary tumor location was found to be associated with resistance to anti-EGFRs, confirming previous literature evidence. Overall, the combined evaluation of the PRESSING panel and primary tumor location demonstrated the best predictive accuracy. These results open novel perspectives on the clinical application of a more comprehensive molecular characterization of *RAS*/*BRAF* WT mCRCs to further improve and refine patient selection for anti-EGFR treatment and possibly tailor personalized targeted approaches.

Clonal selection induced by treatment pressure is often responsible for the development of secondary resistance to EGFR inhibitors, and emerging mutations in the RAS/RAF/MAPK pathway can be identified in tumor samples at progression in patients previously diagnosed with a *RAS* WT tumors.[@CIT0071] Several trials are investigating different approaches to multiple target inhibition based on the emergence of different resistance drivers. In this setting, the use of liquid biopsies and the analysis of circulating tumor DNA (ctDNA) are being evaluated as a less invasive and more comprehensive approach to pharmacogenomic profiling and biomarkers monitoring in mCRC patients.[@CIT0072] These techniques might play, in the near future, a pivotal role in improving patient selection and targeted treatment strategies by implementing early detection of the emergence of treatment resistance and allowing a dynamic molecular profiling.[@CIT0073] Indeed, repeated ctDNA analyses have been able to capture the emergence of resistant clones during treatment with panitumumab or cetuximab in *RAS* WT patients, showing that this phenomenon is closely related to treatment exposure, with a dynamic increase during anti-EGFRs administration followed by a rapid decline at withdrawal.[@CIT0074],[@CIT0075] In a recent biomarker analysis from a second-line phase II trial of panitumumab in association with irinotecan in *KRAS* WT mCRC, plasma testing of cell-free DNA revealed a mutant *RAS* emergence rate of 36.7% (n=39), and first detected emergence of *RAS* mutations preceded progression by a median of 3.6 months (range, 0.3--7.5).[@CIT0076] However, patients who had emergent *RAS* mutations at progression had similar median PFS to those who remained WT and a mutant *RAS* allele frequency threshold that could predict near-term outcomes was not identified, thus calling for further evaluation of the clinical value of this approach. Interestingly, recently published results from retrospective analyses evaluating emergent mutations in circulating cell-free DNA in patients treated with panitumumab in the ASPECCT study showed that patients with a higher *RAS* mutant allele frequency at baseline had worse clinical outcomes than those with a lower frequency (*P*\<0.001). However, extended *RAS* mutation, by itself, did not preclude clinical responses to panitumumab in this setting and emergent ctDNA *RAS* mutations were not associated with less favorable patient outcomes in panitumumab-treated patients.[@CIT0077],[@CIT0078] Further research is needed to identify a clinically relevant threshold for baseline and emergent ctDNA *RAS* mutations.

Of note, focusing on the issue of analytical sensitivity in evaluating predictive biomarkers to anti-EGFR treatments, the phase II ULTRA trial investigated a high-sensitivity tumor tissue genotyping technique of *KRAS, NRAS, BRAF* and *PIK3CA* to ultra-select irinotecan-resistant mCRC patients for panitumumab plus FOLFIRI treatment. Results from this study identify the optimal *RAS/BRAF* mutational threshold for outcome prediction to be 5%, suggesting that the biological and clinical implications of mutation frequencies below this cut-off still warrant further investigations.[@CIT0079]

Finally, re-challenge strategies after treatment breaks in patients with *RAS* WT tumors that demonstrated a previous response to anti-EGFR agents are currently under study. The phase II CHRONOS study (NCT03227926) aims to investigate a re-challenge strategy with panitumumab as third-line treatment after a first-line treatment with anti-EGFRs in *RAS*/*BRAF* WT mCRC, with a molecular follow-up based on ctDNA. In this study liquid biopsies for ctDNA testing are prospectively collected during the first-line and the re-challenge phases to test the correlation between circulating ctDNA biomarkers and treatment response. Interestingly, the possibility of continuing panitumumab beyond progression is also being investigated in a multicenter single-arm phase II Japanese clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab in initial *RAS* WT mCRC (UMIN000026817). Mutational status using ctDNA will be prospectively assessed at multiple time-points during this study as one of the planned secondary endpoints.

Conclusions {#S0007}
===========

Panitumumab in association with chemotherapy is a valuable first- or second-line treatment option in patients with *RAS* WT mCRC, as well as a monotherapy option in advanced lines for chemorefractory patients. The toxicity profile of panitumumab is manageable and this agent has a favorable impact on patient's QoL, showing positive results also in the population of frail and elderly mCRC patients. Novel treatment scenarios are opening for panitumumab including combinations with intensified chemotherapy regimens to implement conversion to resectability in initially unresectable patients and maintenance treatment strategies. The development of panitumumab has significantly added to the treatment options for *RAS* WT mCRC, and has contributed to expanding the horizons of mCRC molecular profiling.

Current efforts are directed to dissect the mechanisms of primary resistance beyond *RAS* status and the mechanisms of acquired resistance to panitumumab (and more generally anti-EGFRs), which entails a more comprehensive molecular characterization of *RAS* WT tumors, the assessment of additional mutational and clinico-pathological features, ie *BRAF* status and tumor sidedness, and the development of novel technologies to capture the dynamic heterogeneity of the genomic landscape displayed by mCRC under targeted treatment pressure. Recent advancements in this field warrant a prospective validation of new predictive biomarkers in *RAS* WT mCRC, in order to further refine patient selection and develop novel molecularly-tailored treatment strategies to optimize outcomes and patients benefit.
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[^1]: **Abbreviations:** BSC, best supportive care; CI, confidence interval; ex, exon; HR, hazard ratio; m, months; n, number of patients; NE, not evaluated; PFS, progression free survival; ORR, objective response rate; OS, overall survival; Ref, reference; WT, wild-type.
